Evidence map›Paper›PMID 41212833›Full record

ArticleJournal of visualized experiments : JoVE2025

Leucine Zipper-based Cell Sorting for Purification of Dual-vector-transduced Cells.

Katerina Su, Bintao Wang, Adhithi Rajagopalan, Sophia Chen, Alexander P Boardman, Marcel R M van den Brink, Scott E James

Abstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Katerina Su *City of Hope Los Angeles and National Medical Center.
Bintao Wang *City of Hope Los Angeles and National Medical Center.
Adhithi RajagopalanCity of Hope Los Angeles and National Medical Center.
Sophia ChenCity of Hope Los Angeles and National Medical Center.
Alexander P BoardmanLymphoma and Cellular Therapy Services, Memorial Sloan Kettering Cancer Center.
Marcel R M van den Brink *City of Hope Los Angeles and National Medical Center; mvandenbrink@coh.org.
Scott E James *City of Hope Los Angeles and National Medical Center; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center; scjames@coh.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
T LYMPHOCYTE SUBSET FUNCTION POST-TRANSPLANTATIONP01CA023766 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SCHEINBERG, DAVID A · 1985 to 2023
$59.0M
Thymic and Peripheral Aspects of T Cell Aging and RejuvenationP01AG052359 · NIA · UNIVERSITY OF ARIZONA · PI JANKO Z. NIKOLICH · 2017 to 2026
$23.5M
The role of intestinal microbiota in graft-versus-host diseaseR01CA228308 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Philip L Lorenzi, Marcel R M van den Brink · 2018 to 2026
$5.2M
The role of the intestinal microbiome in cancer immunotherapyR35CA284024 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Marcel R M van den Brink · 2023 to 2026
$4.2M
Intestinal microbiome restoration in allogeneic stem cell transplantationR01HL164902 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI Doris Ponce, Marcel R M van den Brink · 2023 to 2026
$1.8M
Multi-antigen-specific CAR T cells to treat acute myeloid leukemiaK08CA252157 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JAMES, SCOTT E · 2020 to 2024
$1.3M
NCI NIH HHS K08 CA252157NCI NIH HHS P01 CA023766NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA228308NCI NIH HHS R35 CA284024NHLBI NIH HHS R01 HL164902NIA NIH HHS P01 AG052359
6 · The paper itself

Abstract

Adoptive T cell therapies, including chimeric antigen receptor (CAR) T cells, have demonstrated impressive clinical activity against hematologic malignancies and are showing promise in treating solid tumor malignancies. Despite these successes, multiple mechanisms of resistance to T cell immunotherapy have been identified that limit therapeutic success, including loss of or weak expression of target antigens, development of T cell exhaustion, and the presence of an immunosuppressive tumor microenvironment. Multiple cell engineering strategies have been developed to overcome these mechanisms of resistance. However, multiple mechanisms of resistance can occur simultaneously, necessitating a combination of multiple engineering strategies to optimize anti-tumor activity. Vector packaging constraints limit the delivery of large amounts of genetic information to T cells and present a challenge in co-expressing multiple engineered constructs. Here, we describe a protocol for co-transducing T cells with two vectors to encode multiple transgenes, thereby increasing the number of engineered functions. By co-expressing a leucine zipper-based cell sorting methodology, termed Zip-sort, we direct selective immunomagnetic purification of dual-transduced cells that have incorporated two distinct vectors.

Indexed as

Genetic VectorsLeucine ZippersT-LymphocytesTransduction, GeneticHumansReceptors, Chimeric AntigenReceptors, Chimeric Antigen

Identifiers

PMID41212833
PMCPMC12931735

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.